Phase 2 Trial of Probody-Opdivo Combo Expanding in Advanced Cancers

Source: Immuno-Oncology News, March 2020

An ongoing Phase 1/2a trial exploring a type of engineered antibody — the anti-CTLA-4 probody BMS-986249 by CytomX Therapeutics — alone and in combination with Opdivo (nivolumab) in treating advanced solid tumors is expanding to include people with melanoma.

This randomized Phase 2 part of the study (NCT03369223) will assess if a combination of BMS-986249 and Bristol-Myers‘ Opdivo, both immune checkpoint inhibitors, is better than Opdivo alone in melanoma patients whose cancer has spread to distant sites.

Bristol-Myers is leading the trial, which is expected to enroll 375 people across sites in the U.S., Canada, Australia, and Europe.

Read the original full article